NCT05377827View on ClinicalTrials.gov

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 10, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
T-Cell Non-Hodgkin LymphomaAcute Myeloid LeukemiaAngioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaPeripheral T Cell LymphomaAnaplastic Large Cell LymphomaAdult T Cell LeukemiaAdult T Cell LymphomaT Cell Prolymphocytic LeukemiaExtranodal NK/T-cell LymphomaTransformed Mycosis FungoidesSezary SyndromePrimary Cutaneous Gamma-Delta T-Cell LymphomaHepatosplenic T-cell Lymphoma
Interventions
BIOLOGICAL

WU-CART-007

Provided by Miltenyi Biotec

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Wugen, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER